Streetbeat News

Analyst Ratings

TVTX

Travere Therapeutics' shares rose following FDA's full approval of FILSPARI for treating primary IgAN. HC Wainwright & Co also maintained a Buy rating and increased the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:32 am

GIFI

NFE

TRMD

VTLE

The article highlights four energy stocks with low RSI values, indicating they are oversold and may present buying opportunities. These stocks include Vital Energy Inc (VTLE), Torm PLC (TRMD), New Fortress Energy Inc (NFE), and Gulf Island Fabrication, Inc. (GIFI).

Portfolio Pulse from Avi Kapoor

September 06, 2024 | 11:32 am

IOT

B of A Securities analyst Matt Bullock maintains a Buy rating on Samsara (NYSE:IOT) and raises the price target from $45 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:31 am

DC

BMO Capital has initiated coverage on Dakota Gold with an Outperform rating and set a price target of $6. Analyst Andrew Mikitchook is optimistic about the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:29 am

AKBA

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akebia Therapeutics, maintaining a price target of $7.5.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:27 am

PHR

Baird analyst Joseph Vruwink maintains an Outperform rating on Phreesia (NYSE:PHR) and raises the price target from $31 to $34.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:27 am

GWRE

Baird analyst Joe Vruwink has maintained an Outperform rating on Guidewire Software (NYSE:GWRE) and raised the price target from $165 to $175.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:26 am

TVTX

HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics and raised the price target from $20 to $23, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:22 am

DOCU

Baird analyst William Power maintains a Neutral rating on DocuSign (NASDAQ:DOCU) and raises the price target from $55 to $59.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:17 am

TTC

Baird analyst Timothy Wojs maintains a Neutral rating on Toro (NYSE:TTC) and lowers the price target from $102 to $92.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:16 am